279 related articles for article (PubMed ID: 22964999)
1. Inhibition of PCSK9: is this the way forward for managing residual risk?
Chowdhury SR; Rees A
Curr Opin Lipidol; 2012 Oct; 23(5):509-10. PubMed ID: 22964999
[No Abstract] [Full Text] [Related]
2. Winner by points?--LDL cholesterol as a target for therapeutic intervention.
Tietge UJ
Curr Opin Lipidol; 2013 Jun; 24(3):277-8. PubMed ID: 23652473
[No Abstract] [Full Text] [Related]
3. Therapy and clinical trials.
Sodhi N; Krasuski RA
Curr Opin Lipidol; 2013 Jun; 24(3):281-2. PubMed ID: 23652475
[No Abstract] [Full Text] [Related]
4. PCSK9 inhibitors.
Farnier M
Curr Opin Lipidol; 2013 Jun; 24(3):251-8. PubMed ID: 23652470
[TBL] [Abstract][Full Text] [Related]
5. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
6. Normalization of low-density lipoprotein receptor expression in receptor defective homozygous familial hypercholesterolemia by inhibition of PCSK9 with alirocumab.
Lambert G; Chatelais M; Petrides F; Passard M; Thedrez A; Rye KA; Schwahn U; Gusarova V; Blom DJ; Sasiela W; Marais AD
J Am Coll Cardiol; 2014 Dec; 64(21):2299-300. PubMed ID: 25456764
[No Abstract] [Full Text] [Related]
7. [Antibodies in addition to statin therapy lowers LDL cholesterol].
Bossenmayer S
Dtsch Med Wochenschr; 2012 Sep; 137(36):1728. PubMed ID: 23281534
[No Abstract] [Full Text] [Related]
8. [Inhibition of the protein PCSK9 is a promising target in the prevention of cardiovascular disease].
Christiansen MK; Jensen HK
Ugeskr Laeger; 2015 Mar; 177(11):. PubMed ID: 25786699
[TBL] [Abstract][Full Text] [Related]
9. [Lipid control in high-risk patients: focus on PCSK9 inhibitors].
Filardi PP; Paolillo S; Trimarco B
G Ital Cardiol (Rome); 2015 Jan; 16(1):44-51. PubMed ID: 25689751
[TBL] [Abstract][Full Text] [Related]
10. [New drug development competition for LDL receptor].
Fujita T
Nihon Yakurigaku Zasshi; 2014 May; 143(5):262. PubMed ID: 24813799
[No Abstract] [Full Text] [Related]
11. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
[TBL] [Abstract][Full Text] [Related]
12. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins.
Dias CS; Shaywitz AJ; Wasserman SM; Smith BP; Gao B; Stolman DS; Crispino CP; Smirnakis KV; Emery MG; Colbert A; Gibbs JP; Retter MW; Cooke BP; Uy ST; Matson M; Stein EA
J Am Coll Cardiol; 2012 Nov; 60(19):1888-98. PubMed ID: 23083772
[TBL] [Abstract][Full Text] [Related]
13. [Effective LDL cholesterol reduction for high risk patients].
Einecke D
MMW Fortschr Med; 2016 Apr; 158(8):84. PubMed ID: 27116175
[No Abstract] [Full Text] [Related]
14. New weapon in fighting atherosclerosis: effective inhibition of circulating low density lipoprotein cholesterol.
Ginter E; Simko V
Bratisl Lek Listy; 2014; 115(12):741-2. PubMed ID: 25520219
[TBL] [Abstract][Full Text] [Related]
15. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction.
Tavori H; Melone M; Rashid S
Expert Rev Cardiovasc Ther; 2014 Oct; 12(10):1137-44. PubMed ID: 25244623
[TBL] [Abstract][Full Text] [Related]
16. [PCSK9 inhibition--A new era in cholesterol treatment].
Olsson A
Lakartidningen; 2015 Feb; 112():. PubMed ID: 25689006
[TBL] [Abstract][Full Text] [Related]
17. Antihyperlipidemic therapies targeting PCSK9: Novel therapeutic agents for lowering low-density lipoprotein cholesterol.
Liu MH
Int J Cardiol; 2015 Sep; 195():212-4. PubMed ID: 26048378
[No Abstract] [Full Text] [Related]
18. Cardiovascular endocrinology in 2012: PCSK9-an exciting target for reducing LDL-cholesterol levels.
Betteridge DJ
Nat Rev Endocrinol; 2013 Feb; 9(2):76-8. PubMed ID: 23296165
[TBL] [Abstract][Full Text] [Related]
19. Beyond LDL cholesterol, a new role for PCSK9.
Akram ON; Bernier A; Petrides F; Wong G; Lambert G
Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1279-81. PubMed ID: 20554949
[No Abstract] [Full Text] [Related]
20. [PCSK9 inhibitor is convincing a large analysis].
Schlimpert V
MMW Fortschr Med; 2015 Dec; 157(21-22):90. PubMed ID: 26960892
[No Abstract] [Full Text] [Related]
[Next] [New Search]
